IPSC · NASDAQ
Century Therapeutics (IPSC) Stock Price & Fundamentals
Century Therapeutics (IPSC) closed at $281.17 on Oct 9, 2026, down 0.02% from the previous close of $281.22.
Share price, past year
1Y +18.65%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $281.17 |
| Sep 30, 2026 | $266.78 |
| Aug 31, 2026 | $270.01 |
| Jul 31, 2026 | $254.70 |
| Jun 30, 2026 | $234.46 |
| May 29, 2026 | $232.66 |
| Apr 30, 2026 | $228.45 |
| Mar 31, 2026 | $222.83 |
| Feb 27, 2026 | $225.46 |
| Jan 30, 2026 | $228.90 |
| Dec 31, 2025 | $225.49 |
| Nov 28, 2025 | $225.75 |
| Oct 31, 2025 | $234.14 |
Key statistics
- Market cap
- $50.76B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.06
- Revenue (TTM)
- —
- Net income (TTM)
- −$109.79M
- Shares outstanding
- 180.5M
- Dividend yield
- —
- 52-week range
- $215.66 – $281.22
Century Therapeutics's market cap is $50.76B, based on a share price of $281.17 and 180.5M shares outstanding as of Jun 30, 2026.
Financials
Century Therapeutics reported revenue of $109.16M for fiscal 2025, up 1,556.76% from fiscal 2024.
Century Therapeutics reported a net loss of $9.58M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $109.16M | +1,556.8% | −$9.58M | −8.8% | −$0.14 | −$104.72M |
| FY2024ended Dec 31, 2024 | $6.59M | +194.8% | −$126.57M | −1,920.9% | −$1.61 | −$110.29M |
| FY2023ended Dec 31, 2023 | $2.24M | −57.0% | −$136.67M | −6,115.1% | −$2.30 | −$102.08M |
| FY2022ended Dec 31, 2022 | $5.20M | — | −$130.93M | −2,518.4% | −$2.96 | −$16.55M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2025ended Mar 31, 2025 | $109.16M | $76.56M | $0.89 |
| Q4 FY2024ended Dec 31, 2024 | $4.17M | −$36.07M | — |
| Q3 FY2024ended Sep 30, 2024 | $791.00K | −$31.23M | −$0.37 |
| Q2 FY2024ended Jun 30, 2024 | $771.00K | — | −$0.38 |
| Q1 FY2024ended Mar 31, 2024 | $855.00K | — | −$0.45 |
| Q4 FY2023ended Dec 31, 2023 | $268.00K | — | — |
| Q3 FY2023ended Sep 30, 2023 | $148.00K | — | — |
| Q2 FY2023ended Jun 30, 2023 | $99.00K | — | — |
Company profile
- Name
- Century Therapeutics, Inc.
- Ticker
- IPSC
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 25 N 38th Street, 12th Floor, Philadelphia, PA
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001850119
Recent SEC filings
- Oct 2, 2026
- Sep 9, 2026
- Aug 12, 2026
- Aug 12, 2026
- Jun 16, 2026
- Jun 12, 2026
- Jun 8, 2026
- May 13, 2026
Frequently asked questions
What is Century Therapeutics's stock price?
Century Therapeutics (IPSC) closed at $281.17 on Oct 9, 2026, down 0.02% from the previous close of $281.22.
What is Century Therapeutics's market cap?
Century Therapeutics's market cap is $50.76B, based on a share price of $281.17 and 180.5M shares outstanding as of Jun 30, 2026.
How much revenue does Century Therapeutics make?
Century Therapeutics reported revenue of $109.16M for fiscal 2025, up 1,556.76% from fiscal 2024.
Does Century Therapeutics pay a dividend?
Century Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Century Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures